The Federal Reserve’s decision to hold rates steady under new Chair Kevin Warsh, while inflation sits at 4.2% and energy costs stay pressured by the war in Iran, puts low volatility stocks back in focus. With the Fed hinting at shorter, less guided communication and potential changes to how policy is run, price swings could become harder to read. This article looks at three stocks from a Low Volatility Stocks screener that appear more directly exposed to this news. Each could offer a different way to position around steadier rates and elevated inflation risk.

EMIS Group (AIM:EMIS)

Overview: EMIS Group provides healthcare software and digital tools that connect GP practices, pharmacies, community services and patients across the UK. These tools help clinicians manage records and workflows while giving patients access to information and services online.

Operations: EMIS Group generates most of its revenue from EMIS Health at around £105.4m, with EMIS Enterprise contributing about £71.5m, and the vast majority of sales coming from the United Kingdom.

Market Cap: £1.23b

EMIS Group stands out in a higher rate, higher inflation setting because its healthcare IT platforms are tied into everyday NHS and pharmacy operations, which often supports steadier demand than more cyclical sectors. Earnings growth of around 11% per year is paired with a high 23% ROE and rising profit margins. This suggests the business is converting that demand into solid profitability, although some results are affected by one off items. The trade off is valuation, with a P/E above both its own estimated fair P/E and the wider European healthcare services sector, and a balance sheet funded entirely by external borrowing. For investors, the key question is whether the quality of these recurring revenues justifies paying a higher valuation in exchange for lower volatility exposure to UK healthcare IT.

EMIS Group’s high ROE and recurring NHS linked revenues create an intriguing tension with its richer P/E. Get the full picture on whether that premium stacks up in the DCF valuation analysis for EMIS Group

R1 RCM (RCM)

Overview: R1 RCM helps hospitals and physician groups manage the financial side of patient care by running and improving their revenue cycle, from billing and coding through to collections and compliance, using software, data and outsourced services. The aim is to help healthcare providers get paid accurately and on time while giving patients a smoother, clearer billing experience.

Operations: R1 RCM generates about US$2.46b in revenue from providing management services of revenue cycle operations.

Market Cap: US$6.04b

R1 RCM sits at the crossroads of healthcare and financial technology, which can be attractive when interest rates stay high and investors look for businesses with relatively steady demand. The company is still loss making and Return on Equity is weak, yet forecasts point to faster revenue growth than the broader US market and potential movement into profitability over the next few years. Its valuation screens as very cheap against one estimate of fair value, but the P/S multiple is above a fair price estimate and the balance sheet leans heavily on external borrowing. For investors, the key question is how its AI driven Phare OS platform and strong customer uptake translate into sustainable profits and whether that justifies the current discount.

R1 RCM’s revenue engine and AI driven Phare OS hint at an earnings profile the market may not be fully pricing in yet. See how the growth story lines up with reality in the analyst forecasts for R1 RCM

Smith & Nephew (LSE:SN.)

Overview: Smith & Nephew is a global medical devices company that makes joint replacement implants, surgical tools for sports medicine and ear, nose and throat procedures, and advanced products for treating complex wounds and ulcers for hospitals and clinicians worldwide.

Operations: Smith & Nephew generates most of its revenue from Orthopaedics at about US$2.4b, followed by Sports Medicine & ENT at roughly US$1.9b and Advanced Wound Management at around US$1.8b.

Market Cap: £9.61b

Smith & Nephew offers a mix of lower volatility healthcare exposure and clearly defined growth angles, which can be appealing when Fed policy communication becomes harder to read and inflation stays elevated. Earnings growth has recently outpaced the wider Medical Equipment sector and margins have improved, helped by new products such as the CORI XT robotics platform and advances in wound care and patient monitoring. At the same time, the stock trades on a P/E below peers, with analysts’ targets above the current price. Investors are also weighing risks from high debt, reimbursement changes and inflation in input costs that management has openly acknowledged. The key consideration is whether this combination of product momentum, valuation characteristics and execution risks suits your approach to defensive growth.

Smith & Nephew’s combination of lower P/E, product momentum and rising margins suggests the market may be missing something. See how those pieces fit together in the analysis report for Smith & Nephew

The three stocks here are just a starting point, with the full Low Volatility Stocks screener surfacing 6 more companies across utilities, consumer goods and healthcare that carry similarly compelling stories around stability, balance sheet strength and business quality, all available through the Low Volatility Stocks screener. Use Simply Wall St to identify and analyze the specific catalysts, risk profiles and narratives that matter most to you so you can focus on the higher conviction opportunities that fit your approach.

Take Control of Your Investment Journey

If R1 RCM or any of these companies sound like a great opportunity, register for FREE with Simply Wall St and add your companies to a Watchlist to monitor the share price against the fair value the ideal entry point. Once you've made your move, manage your holdings with our Portfolio Command Center that filters out the noise to deliver only the most critical, actionable updates. Throughout your journey, our Community allows you to filter the best ideas from thousands of investor perspectives. By uncovering hidden catalysts and risks early, you'll accelerate your decision-making and stay one step ahead of the market.

Seeking Fresh Alternatives Before They Fly?

Markets move fast, and the most attractive breakout opportunities rarely stay quiet for long. Tap into fresh stock ideas under the radar for now, before the momentum gets caught, and act now.

• Spot companies with cash rich balance sheets and steady fundamentals by scanning the curated list of solid balance sheet and fundamentals (18 results) while it still highlights under followed prospects.
• Explore long term infrastructure themes by combing through the selected 34 power grid technology and infrastructure stocks and reviewing which businesses might benefit if energy systems keep evolving.
• Look for potential compounders in automation by reviewing the curated 31 robotics and automation stocks and identifying businesses that could strengthen as robotics adoption keeps spreading across industries.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.